Abbott Laboratories Gains Momentum with Key Regulatory Approval
Published on 12/22/2025 at 10:23 | Redaktion boerse-global.de
Shares of medical device leader Abbott Laboratories opened the week on stable footing following a significant regulatory achievement. The company has secured U.S. Food and Drug Administration (FDA) and European approvals for its “Amplatzer Piccolo
Delivery System,” a device designed to treat a life-threatening heart condition in premature infants. This milestone reinforces the strength of Abbott’s specialized portfolio within the pediatric cardiology market.
This regulatory success arrives during a period of strategic growth for the healthcare giant. In a major move to bolster its diagnostics division, Abbott announced in Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
